Back

The clinical profile of a non-selected population treated with sacubitril/valsartan is different from PARADIGM-HF trial

26 May 2018 (09:12 - 09:18)
Organised by:
Congress Presentation Part of: Heart failure prognosis and the options to improve Treatment HFA Premium Access Heart Failure 2018

About the speaker

Photo
Doctor Lourdes Vicent Alaminos

12th of October University Hospital, Madrid (Spain)

14 More presentations in this session

Presentation thumbnail
The impact of anthropometric measures of obesity on heart failure outcomes in Asia
Doctor C. Chandramouli (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
S2PLIT Score: a simple risk score predicting post-discharge 1-year mortality in patients with acutely decompensated heart failure
Mr J. Borovac (Split, HR)
Abstract Slides Video
Presentation thumbnail
Increased all-cause mortality in newly diagnosed patients with heart failure between 2006 and 2012: a retrospective, population-based study in Sweden
Professor K. Lindmark (Umea, SE)
Presentation thumbnail
One year follow-up of heart failure patients: role of the new tnm-like classification
Doctor M. Pucci (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Sacubitril/valsartan initiation among renin-angiotensin aldosterone system inhibitor-naive heart failure patients with reduced ejection fraction
Doctor A. Mohanty (Salt Lake City, US)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure prognosis and the options to improve

The Event

Event poster

Heart Failure 2018

26 May 2018 09:12 CET
You may be interested in
thumbnail
Congress Session
Meet the Experts: summation of the science - treatment of chronic heart failure in 2023
thumbnail
Congress Session
Which device might help your HFpEF patient?
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources